Literature DB >> 21239244

Protein S and protein C Biochemistry, physiology, and clinical manifestation of deficiencies.

C T Esmon1.   

Abstract

Protein C and protein S are two plasma proteins that participate in an anticoagulant pathway. Protein C circulates as an inactive precursor that is converted to an active serine protease by a complex between thrombin and the endothelial cell-surface protein thrombomodulin. Activated protein C and protein S form an anticoagulant complex on cell surfaces that inactivates two of the regulatory proteins of coagulation, factors Va and VIIIa. Activated protein C is then cleared from the circulation by a relatively slow inactivation by α(1) antitrypsin and the protein C inhibitor. Deficiencies in protein C and protein S are associated with thrombotic complications. With protein S, this can arise as the result of a deficiency in protein S synthesis, proteolytic cleavage, and/or due to an increase in binding to the complement regulatory protein C4bBP, which behaves like an acute phase reactant. Inflammatory mediators not only elevate C4bBP levels, but also lead to downregulation of thrombomodulin expression. Animal experiments suggest that activated protein C and protein S may be effective and safe antithrombotic agents.
Copyright © 1992. Published by Elsevier Inc.

Entities:  

Year:  1992        PMID: 21239244     DOI: 10.1016/1050-1738(92)90027-P

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  6 in total

1.  Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies.

Authors:  Omid Safa; Charles T Esmon; Naomi L Esmon
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

2.  Thrombin spatial distribution determines protein C activation during hemostasis and thrombosis.

Authors:  Tanya T Marar; Chelsea N Matzko; Jie Wu; Charles T Esmon; Talid Sinno; Lawrence F Brass; Timothy J Stalker; Maurizio Tomaiuolo
Journal:  Blood       Date:  2022-03-24       Impact factor: 22.113

3.  Regulation of human platelet aggregation by genetically modified pig endothelial cells and thrombin inhibition.

Authors:  Hayato Iwase; Burcin Ekser; Hidetaka Hara; Carol Phelps; David Ayares; David K C Cooper; Mohamed B Ezzelarab
Journal:  Xenotransplantation       Date:  2013-11-05       Impact factor: 3.907

4.  Loss of ATP diphosphohydrolase activity with endothelial cell activation.

Authors:  S C Robson; E Kaczmarek; J B Siegel; D Candinas; K Koziak; M Millan; W W Hancock; F H Bach
Journal:  J Exp Med       Date:  1997-01-06       Impact factor: 14.307

5.  A Case of Type 2 Protein S Deficiency Presenting as Cerebral Venous Thrombosis (CVT) in an 18-Year-Old Female.

Authors:  Ankush Agarwal S; Jennie Santhanam; Arun K; Sruthi Degapudi; Subramaniyan K
Journal:  Cureus       Date:  2022-08-20

6.  Protein C activity as a potential prognostic factor for nursing home-acquired pneumonia.

Authors:  Issei Oi; Isao Ito; Naoya Tanabe; Satoshi Konishi; Nobuyoshi Hamao; Masahiro Shirata; Seiichiro Imai; Yoshiro Yasutomo; Seizo Kadowaki; Hisako Matsumoto; Yu Hidaka; Satoshi Morita; Toyohiro Hirai
Journal:  PLoS One       Date:  2022-10-12       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.